The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer

Adams, M., Navabi, H., Croston, D., Coleman, Sharon Louise, Tabi, Zsuzsanna, Clayton, Aled ORCID: https://orcid.org/0000-0002-3087-9226, Jasani, Bharat and Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869 2005. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23 (17-18) , pp. 2374-2378. 10.1016/j.vaccine.2005.01.014

Full text not available from this repository.

Abstract

A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	Elsevier
ISSN:	0264-410X
Last Modified:	12 Apr 2024 06:24
URI:	https://orca.cardiff.ac.uk/id/eprint/60795

Citation Data

Cited 65 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item